AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11451263 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise to Bruce stage 3 or Duke score >-6 at five years
Number of subjects: 1678
Study 11451263 — intervention group
Group type: EXPERIMENTAL
Intervention: ST depression on the one-year test
Number of subjects: 1678
Study 9407641 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 26
Study 9407641 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 26
Study 7971126 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (95% grain alcohol; mean estimated blood alcohol level = .088%)
Number of subjects: 12
Study 7971126 — intervention group
Group type: COMPARATOR
Intervention: Alcohol placebo
Number of subjects: 12
Study 7971126 — intervention group
Group type: COMPARATOR
Intervention: Sober condition
Number of subjects: 12
Study 2885202 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8
Study 2885202 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 8
Study 2885202 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 8
Study 2885202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31638843 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betamethasone 0.1%
Number of subjects: 90
Study 31638843 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nepafenac 0.1%
Number of subjects: 90
Study 31638843 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anti-inflammatory agent)
Number of subjects: 90
Study 28748705 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pumping (SAP) in the STAR 3 trial
Number of subjects: 0
Study 28748705 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-integrated pumping with low-glucose threshold suspend (SIP+TS) in the ASPIRE In-Home trial
Number of subjects: 0
Study 27387954 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver intervention targeting national fundamental values, consisting of eight guided face-to-face seminars.
Number of subjects: 80
Study 27387954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 80
Study 24656944 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray formulation containing 0.2% sodium hyaluronate and 3% tobramycin
Number of subjects: 27
Study 24656944 — intervention group
Group type: COMPARATOR
Intervention: Nasal spray formulation containing 0.2% sodium hyaluronate alone
Number of subjects: 27
Study 23026255 — intervention group
Group type: COMPARATOR
Intervention: 2-D navigation (group A)
Number of subjects: 34
Study 23026255 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D navigation (group B)
Number of subjects: 34
Study 21061762 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene-BPO (adapalene 0.1% and benzoyl peroxide 2.5%)
Number of subjects: 2453
Study 18294813 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived failure to attain personal goals
Number of subjects: 0
Study 18294813 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual dysfunction
Number of subjects: 0
Study 15992885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily for a maximum of 12 weeks
Number of subjects: 130
Study 15992885 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone (Control)
Number of subjects: 130
Study 15992885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin group
Number of subjects: 130
Study 15992885 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 130
Study 15992885 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study 12800399 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous suture device
Number of subjects: 167
Study 12800399 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 167
Study 10974130 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg, given at 12-hour intervals)
Number of subjects: 148
Study 10974130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (first dose of 10 mg/kg, followed by two doses of 5 mg/kg at 24-hour intervals)
Number of subjects: 148
Study 10974130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 148
Study 10974130 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 148
Study 10974130 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin and Ibuprofen
Number of subjects: 148
Study 8781823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamiphylline (5 mg.kg‐1)
Number of subjects: 36
Study 8781823 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 36
Study 8331207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftazidime 1 g
Number of subjects: 8
Study 8331207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal ceftazidime 1 g
Number of subjects: 8
Study 2867861 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (3 mg/kg single dose, oral)
Number of subjects: 16
Study 2867861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30400221 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g for 6 days followed by 2 g until the end of the study)
Number of subjects: 30
Study 30400221 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 30
Study 30400221 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carboxymethyl cellulose)
Number of subjects: 30
Study 27543590 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-care support intervention
Number of subjects: 54
Study 27543590 — intervention group
Group type: COMPARATOR
Intervention: Leave-on emollients
Number of subjects: 54
Study 24962246 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia group (sleep in a normobaric hypoxia chamber)
Number of subjects: 40
Study 24962246 — intervention group
Group type: COMPARATOR
Intervention: Control group (sleep in normal conditions)
Number of subjects: 40
Study 21985440 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated oral appliance (R)
Number of subjects: 65
Study 21985440 — intervention group
Group type: COMPARATOR
Intervention: Stabilisation appliance (S)
Number of subjects: 65
Study 19939717 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component pain and stress self-management group intervention (PASS)
Number of subjects: 156
Study 19939717 — intervention group
Group type: COMPARATOR
Intervention: Individually administered physical therapy (IAPT)
Number of subjects: 156
Study 18430606 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg)
Number of subjects: 24
Study 18430606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16429748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation tubes (VT group)
Number of subjects: 187
Study 16429748 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (WW group)
Number of subjects: 187
Study 12860866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 40 mg once daily
Number of subjects: 826
Study 12860866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 826
Study 11234739 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening for breast cancer
Number of subjects: 0
Study 11234739 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 0
Study 9273229 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) administered subcutaneously at a dose of 2000 U twice weekly (group II)
Number of subjects: 25
Study 9273229 — intervention group
Group type: COMPARATOR
Intervention: Repeated hemodialysis without rHuEPO (group I)
Number of subjects: 25
Study 1353718 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms
Number of subjects: 12
Study 1353718 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 micrograms
Number of subjects: 12
Study 1353718 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 500 micrograms
Number of subjects: 12
Study 1353718 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms vs Formoterol 24 micrograms
Number of subjects: 12
Study 1353718 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 12
Study 3917678 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA human interferon alpha 2 (IFN alpha 2) 2 million IU m‐2 day‐1, s.c., 3 times a week (schedule 1)
Number of subjects: 14
Study 3917678 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA human interferon alpha 2 (IFN alpha 2) 50 million IU m‐2 day‐1, i.v., for 5 consecutive days, every 3 weeks (schedule 2)
Number of subjects: 14
Study 3917678 — intervention group
Group type: EXPERIMENTAL
Intervention: Both schedules of IFN alpha 2
Number of subjects: 14
Study 31227225 — intervention group
Group type: EXPERIMENTAL
Intervention: Explore Transplant @ Home patient‐guided education
Number of subjects: 0
Study 31227225 — intervention group
Group type: EXPERIMENTAL
Intervention: Explore Transplant @ Home educator‐guided education
Number of subjects: 0
Study 31227225 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 0
Study 30341345 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF), oral dose 300 mg/day, initiated at 24 weeks of gestation and continued to 4 weeks after delivery
Number of subjects: 120
Study 30341345 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TDF treatment)
Number of subjects: 120
Study 26675772 — intervention group
Group type: EXPERIMENTAL
Intervention: EAR: 400 IU/d
Number of subjects: 77
Study 26675772 — intervention group
Group type: EXPERIMENTAL
Intervention: RDA: 600 IU/d
Number of subjects: 77
Study 26675772 — intervention group
Group type: COMPARATOR
Intervention: Control: 227 (184-305) IU/d
Number of subjects: 77
Study 25176317 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based intervention including educational, organizational, and behavioral components administered by trained lay personnel.
Number of subjects: 150
Study 25176317 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard coaching without additional intervention components.
Number of subjects: 150
Study 22574965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) and fractional photothermolysis (FP) combination treatment
Number of subjects: 29
Study 22574965 — intervention group
Group type: COMPARATOR
Intervention: Intense pulsed light (IPL) alone
Number of subjects: 29
Study 22574965 — intervention group
Group type: COMPARATOR
Intervention: Fractional photothermolysis (FP) alone
Number of subjects: 29
Study 22574965 — intervention group
Group type: COMPARATOR
Intervention: Intense pulsed light (IPL) and fractional photothermolysis (FP) performed 4 weeks apart
Number of subjects: 29
Study 20860133 — intervention group
Group type: EXPERIMENTAL
Intervention: Simo Decoction Oral Liquid
Number of subjects: 81
Study 20860133 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine for acupoint block
Number of subjects: 81
Study 18479922 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 0
Study 15942768 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise group (AE: n=7)
Number of subjects: 21
Study 15942768 — intervention group
Group type: COMPARATOR
Intervention: Aerobic and resistance exercise group (AE + RE: n=7)
Number of subjects: 21
Study 15942768 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=7)
Number of subjects: 21
Study 11817518 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (up to 800 microg/day)
Number of subjects: 3
Study 9935127 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/d for 4-5 weeks
Number of subjects: 22
Study 9935127 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone treatment
Number of subjects: 22
Study 7801949 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. nitroglycerin (300 micrograms‐bolus)
Number of subjects: 20
Study 7801949 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of i.v. nitroglycerin (150 micrograms) and metoclopramide (20‐mg bolus)
Number of subjects: 20
Study 1980801 — intervention group
Group type: EXPERIMENTAL
Intervention: praziquantel (40 mg/kg)
Number of subjects: 160
Study 1980801 — intervention group
Group type: EXPERIMENTAL
Intervention: oxamniquine (60 mg/kg)
Number of subjects: 160
Study 1980801 — intervention group
Group type: EXPERIMENTAL
Intervention: metrifonate (two doses of 10 mg/kg bodyweight)
Number of subjects: 160
Study 1980801 — intervention group
Group type: COMPARATOR
Intervention: multivitamin preparation
Number of subjects: 160
Study 91436 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (MCT) with CCNU, methotrexate, and vinblastine for 2 years
Number of subjects: 62
Study 91436 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) to the previously involved tumor areas
Number of subjects: 62
Study 91436 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy consisting of bleomycin, vinblastine, Adriamycin, and cis‐dichlorodiammineplatinum(II)
Number of subjects: 62
Study 28240710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent stretching (3 × 30 seconds with 30 seconds rest)
Number of subjects: 16
Study 28240710 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous stretching (90 seconds)
Number of subjects: 16
Study 26861858 — intervention group
Group type: EXPERIMENTAL
Intervention: IV enoxaparin 0.5 mg/kg
Number of subjects: 165
Study 26861858 — intervention group
Group type: COMPARATOR
Intervention: IV unfractionated heparin (UFH)
Number of subjects: 165
Study 26226074 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 40
Study 26226074 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study 23507228 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberries (300 g)
Number of subjects: 10
Study 23507228 — intervention group
Group type: COMPARATOR
Intervention: Control jelly
Number of subjects: 10
Study 21084650 — intervention group
Group type: EXPERIMENTAL
Intervention: Consuming breakfast
Number of subjects: 21
Study 21084650 — intervention group
Group type: COMPARATOR
Intervention: Omitting breakfast
Number of subjects: 21
Study 19377499 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding stent tailored to shield vulnerable plaques (vProtect Luminal Shield)
Number of subjects: 1
Study 19377499 — intervention group
Group type: EXPERIMENTAL
Intervention: Two overlapping drug-eluting stents for the culprit lesion
Number of subjects: 1
Study 17179343 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic sonography
Number of subjects: 285
Study 17179343 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 285
Study 15152896 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 21
Study 15152896 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine 50 mg (active control)
Number of subjects: 21
Study 15152896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11563807 — intervention group
Group type: EXPERIMENTAL
Intervention: QSU‐Brief (10 items)
Number of subjects: 39
Study 11563807 — intervention group
Group type: COMPARATOR
Intervention: Noncraving questionnaire (scale‐based control)
Number of subjects: 39
Study 11563807 — intervention group
Group type: COMPARATOR
Intervention: Time‐based control
Number of subjects: 39
Study 9553478 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact (test group)
Number of subjects: 29
Study 9553478 — intervention group
Group type: COMPARATOR
Intervention: Isonitrogenous isocaloric diet (control group)
Number of subjects: 29
Study 8157729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole administration
Number of subjects: 5
Study 8157729 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 5
Study 3073625 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg x 2 for 5 days)
Number of subjects: 15
Study 3073625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1.5 g x 3 for 3 days, 1 g x 2 days 4 and 5)
Number of subjects: 15
Study 3073625 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen
Number of subjects: 15
Study 3073625 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid
Number of subjects: 15
Study 4360398 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin and cystine
Number of subjects: 0
Study 4360398 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavine and cystine
Number of subjects: 0
Study 4360398 — intervention group
Group type: COMPARATOR
Intervention: Placebos
Number of subjects: 0
Study 30722696 — intervention group
Group type: EXPERIMENTAL
Intervention: Five days of preoperative inspiratory muscle training
Number of subjects: 197
Study 30722696 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 197
Study 27782114 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe energy deficit (SEV: -1062±80 kcal per day)
Number of subjects: 25
Study 27782114 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate energy deficit (MOD: -633±71 kcal per day)
Number of subjects: 25
Study 27782114 — intervention group
Group type: COMPARATOR
Intervention: Energy balance (BAL)
Number of subjects: 25
Study 25167960 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 mg folic acid
Number of subjects: 37
Study 25167960 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid
Number of subjects: 37
Study 23153449 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV fusion protein nanoparticle vaccine (5, 15, 30, and 60 μg with and without aluminum phosphate) administered intramuscularly on day 0 and 30
Number of subjects: 0
Study 23153449 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV fusion protein nanoparticle vaccine
Number of subjects: 0
Study 23153449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21607551 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg once daily
Number of subjects: 1262
Study 21607551 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg once daily
Number of subjects: 1262
Study 21607551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1262
Study 18222354 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of the 719Arg allele of KIF6
Number of subjects: 25283
Study 18222354 — intervention group
Group type: COMPARATOR
Intervention: Noncarriers of the 719Arg allele of KIF6
Number of subjects: 25283
Study 18473981 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 18473981 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting (CAS) with cerebral protection
Number of subjects: 0
Study 18473981 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular techniques
Number of subjects: 0
Study 12702070 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA and topical calcipotriol
Number of subjects: 22
Study 12702070 — intervention group
Group type: COMPARATOR
Intervention: PUVA
Number of subjects: 22
Study 11126835 — intervention group
Group type: EXPERIMENTAL
Intervention: J-shaped atrial lead
Number of subjects: 208
Study 11126835 — intervention group
Group type: COMPARATOR
Intervention: Straight atrial lead
Number of subjects: 208
Study 11126835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both leads
Number of subjects: 208
Study 9193330 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus early CMF (B and D)
Number of subjects: 1266
Study 9193330 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus delayed CMF (C and D)
Number of subjects: 1266
Study 9193330 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen with delayed CMF for ER-negative tumors
Number of subjects: 1266
Study 1397915 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium cleansing solution
Number of subjects: 66
Study 1397915 — intervention group
Group type: COMPARATOR
Intervention: Standard polyethylene glycol electrolyte solution
Number of subjects: 66
Study 1397915 — intervention group
Group type: EXPERIMENTAL
Intervention: Both solutions
Number of subjects: 66
Study 11540865 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine (15 mg p.o., twice daily)
Number of subjects: 20
Study 29845835 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-cross body stretching with scapular stabilization (SS)
Number of subjects: 26
Study 29845835 — intervention group
Group type: COMPARATOR
Intervention: Self-cross body stretching without scapular stabilization (WS)
Number of subjects: 26
Study 29761615 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-1293 insulin glargine (Mk-Gla)
Number of subjects: 531
Study 29761615 — intervention group
Group type: COMPARATOR
Intervention: Lantus (Sa-Gla)
Number of subjects: 531
Study 26614676 — intervention group
Group type: EXPERIMENTAL
Intervention: VONCENTO® (50 IU FVIII/kg body weight)
Number of subjects: 81
Study 26614676 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with VONCENTO®
Number of subjects: 81
Study 26614676 — intervention group
Group type: COMPARATOR
Intervention: Biostate‐RP (reference product)
Number of subjects: 81
Study 25348207 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials (board game, video, or booklet)
Number of subjects: 125
Study 25348207 — intervention group
Group type: COMPARATOR
Intervention: Entertaining material (same format type as educational materials)
Number of subjects: 125
Study 25348207 — intervention group
Group type: COMPARATOR
Intervention: No material (control group)
Number of subjects: 125
Study 22257841 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatal outcomes adjudicated by three cardiology specialists
Number of subjects: 5837
Study 22257841 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatal outcomes adjudicated by three cardiology specialists
Number of subjects: 5837
Study 21135294 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy
Number of subjects: 142
Study 21135294 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 142
Study 17927576 — intervention group
Group type: EXPERIMENTAL
Intervention: Myristyl nicotinate (MN)
Number of subjects: 0